- ►diabetesjournals.org D Kim, L MacConell, D Zhuang, PA Kothare, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by
−1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3%
with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and ... Cited by 127 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 119 - Related articles - BL Direct - All 5 versions
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 132 - Related articles - BL Direct - All 4 versions
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, … - Diabetes Care, 2007 - Am Diabetes Assoc Main inclusion criteria were patients aged ≥18 years with type 2 diabetes and
A1C ≥7.5 and ≤10.0% (diet) or ≥7.0 and ≤9.5% (mono–oral antidiabetes
drug); previous therapy was discontinued. Fasting plasma glucose (FPG) at ... Cited by 116 - Related articles - BL Direct - All 5 versions
V Fonseca, A Schweizer, D Albrecht, MA … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Type 2 diabetes is difficult to manage in patients with
a long history of disease requiring insulin therapy. Moreover, addition of most
currently available oral antidiabetic agents increases the risk of ... Cited by 104 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 329 - Related articles - BL Direct - All 7 versions
- Free from Publisher J Rosenstock, MA Baron, S Dejager, D Mills, … - Diabetes Care, 2007 - ncbi.nlm.nih.gov OBJECTIVE: To compare the efficacy and tolerability of vildagliptin and
rosiglitazone during a 24-week treatment in drug-naïve patients with type 2
diabetes. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, ... Cited by 142 - Related articles - BL Direct - All 5 versions
FX Pi-Sunyer, A Schweizer, D Mills, S Dejager - Diabetes research and clinical practice, 2007 - Elsevier This 24-week, double-blind, randomized, multicenter, placebo-controlled,
parallel-group study performed in 354 drug-naïve patients with type 2 diabetes
(T2DM) assessed efficacy and tolerability of vildagliptin (50 mg qd, 50 mg ... Cited by 119 - Related articles - All 12 versions
RE Ratner, D Maggs, LL Nielsen, AH … - Diabetes Obesity and Metabolism, 2006 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 88 - Related articles - BL Direct - All 7 versions
DC Klonoff, JB Buse, LL Nielsen, X Guan, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2
diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. The
objective of this study was to evaluate the effects of ≥3 years exenatide ... Cited by 91 - Related articles - BL Direct - All 7 versions
